View in EDS

Major partial response to crizotinib, a dual MET/ALK inhibitor, in a squamous cell lung (SCC) carcinoma patient with de novo c-MET amplification in the absence of ALK rearrangement.

Saved in:
Bibliographic Details
Title: Major partial response to crizotinib, a dual MET/ALK inhibitor, in a squamous cell lung (SCC) carcinoma patient with de novo c-MET amplification in the absence of ALK rearrangement.
Authors: Schwab R; KPS Medical Biotechnology and Healthcare Services Ltd., Budapest, Hungary., Petak I; KPS Medical Biotechnology and Healthcare Services Ltd., Budapest, Hungary; Hungarian Academy of Sciences, Pathobiochemistry Research Group, Budapest, Hungary. Electronic address: petak@kps.hu., Kollar M; KPS Medical Biotechnology and Healthcare Services Ltd., Budapest, Hungary., Pinter F; KPS Medical Biotechnology and Healthcare Services Ltd., Budapest, Hungary., Varkondi E; KPS Medical Biotechnology and Healthcare Services Ltd., Budapest, Hungary., Kohanka A; KPS Medical Biotechnology and Healthcare Services Ltd., Budapest, Hungary., Barti-Juhasz H; KPS Medical Biotechnology and Healthcare Services Ltd., Budapest, Hungary., Schönleber J; Semmelweis University, Ist Department of Gynecology, Budapest, Hungary., Brauswetter D; Hungarian Academy of Sciences, Pathobiochemistry Research Group, Budapest, Hungary., Kopper L; Semmelweis University, Ist Institute of Pathology and Experimental Cancer Research, Budapest, Hungary., Urban L; Matrahaza Healthcare Center and University Teaching Hospital, Matrahaza, Hungary.
Source: Lung cancer (Amsterdam, Netherlands) [Lung Cancer] 2014 Jan; Vol. 83 (1), pp. 109-11. Date of Electronic Publication: 2013 Oct 19.
Publication Type: Case Reports; Journal Article; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Elsevier Scientific Publishers Country of Publication: Ireland NLM ID: 8800805 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1872-8332 (Electronic) Linking ISSN: 01695002 NLM ISO Abbreviation: Lung Cancer Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1872-8332
DOI:10.1016/j.lungcan.2013.10.006